stoxline Quote Chart Rank Option Currency Glossary
  
Bluejay Diagnostics, Inc. (BJDX)
3.41  -0.22 (-6.06%)    02-18 16:00
Open: 3.737
High: 3.74
Volume: 9,802
  
Pre. Close: 3.63
Low: 3.37
Market Cap: 2(M)
Technical analysis
2025-02-18 4:42:19 PM
Short term     
Mid term     
Targets 6-month :  5.37 1-year :  6.3
Resists First :  4.59 Second :  5.4
Pivot price 3.62
Supports First :  3.29 Second :  2.74
MAs MA(5) :  3.64 MA(20) :  3.71
MA(100) :  4.45 MA(250) :  94.24
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  26.8 D(3) :  28.7
RSI RSI(14): 44.1
52-week High :  386.79 Low :  3.02
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BJDX ] has closed above bottom band by 28.8%. Bollinger Bands are 51.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.75 - 3.77 3.77 - 3.79
Low: 3.32 - 3.35 3.35 - 3.37
Close: 3.37 - 3.41 3.41 - 3.44
Company Description

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Headline News

Wed, 13 Nov 2024
Bluejay Diagnostics Announces Reverse Stock Split - Yahoo Finance

Wed, 13 Nov 2024
Bluejay Diagnostics Implements 1-for-50 Reverse Stock Split, Reduces Shares to 552K - StockTitan

Fri, 28 Jun 2024
Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering - Yahoo Finance

Sat, 02 Mar 2024
symbol__ Stock Quote Price and Forecast - CNN

Tue, 02 Jan 2024
Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering - GlobeNewswire

Wed, 27 Dec 2023
Bluejay Diagnostics, Inc. Announces Initiation of - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 1 (M)
Shares Float 1 (M)
Held by Insiders 0.6 (%)
Held by Institutions 6.6 (%)
Shares Short 14 (K)
Shares Short P.Month 13 (K)
Stock Financials
EPS -804
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 20.09
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -60.8 %
Return on Equity (ttm) -138.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -14.46
Qtrly Earnings Growth 0 %
Operating Cash Flow -9 (M)
Levered Free Cash Flow -7 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0.16
Price to Sales 0
Price to Cash Flow -0.22
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android